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Abstract
Background Subjective complaints of cognitive deficits are not necessarily consistent with objective evidence of cognitive 
impairment in Parkinson’s disease (PD). Here we examined the factors associated with the objective-subjective cognitive 
discrepancy.
Methods We consecutively enrolled 90 non-demented patients with PD who completed the Parkinson’s Disease Cognitive 
Functional Rating Scale (subjective cognitive measure) and the Montreal Cognitive Assessment (MoCA; objective cognitive 
measure). The patients were classified as “Overestimators”, “Accurate estimators”, and “Underestimators” on the basis of the 
discrepancy between the objective vs. subjective cognitive measures. To identify the factors distinguishing these groups from 
each other, we used chi-square tests or one-way analyses of variance, completed by logistic and linear regression analyses.
Results Forty-nine patients (54.45%) were classified as “Accurate estimators”, 29 (32.22%) as “Underestimators”, and 12 
(13.33%) as “Overestimators”. Relative to the other groups, the “Underestimators” scored higher on the Fatigue Severity 
Scale (FSS), Beck Depression Inventory (BDI), and Parkinson Anxiety Scale (p < 0.01). Logistic regression confirmed that 
FSS and BDI scores distinguished the “Underestimators” group from the others (p < 0.05). Linear regression analyses also 
indicated that FSS and BDI scores positively related to objective-subjective cognitive discrepancy (p < 0.01). “Overestima-
tors” scored lower than other groups on the MoCA’s total score and attention and working memory subscores (p < 0.01).
Conclusion In more than 45% of consecutive non-demented patients with PD, we found a ‘mismatch’ between objective and 
subjective measures of cognitive functioning. Such discrepancy, which was related to the presence of fatigue and depressive 
symptoms and frontal executive impairments, should be carefully evaluated in clinical setting.
Keywords Fatigue · Depression · Cognitive impairment · Subjective cognitive decline · Mild cognitive impairment
Introduction
Cognitive impairment is a frequent, pervasive and progres-
sive non-motor manifestation of Parkinson’s disease (PD) 
[1]. Considering the negative impact of cognitive deficits 
on patients’ quality of life and functional independence 
[2], the International Parkinson and Movement Disorders 
Society (MDS) proposed consensus criteria for identifying 
mild cognitive impairment (MCI) in PD. This syndrome is 
characterized by objective cognitive deficits in addition to 
subjective complaints of cognitive impairments observed by 
either the patient, informant or clinician [1] and occurs in 
approximately 40% of PD population [3].
However, it is difficult to rely on patients’ subjective 
reports of cognitive functioning, as around half of the 
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patients with PD tend to judge their own cognitive perfor-
mances as better or worse than their actual performances on 
objective cognitive testing [4].
Previous studies on the relationships between subjective 
cognitive complaints and objective cognitive impairment in 
PD led to conflicting results. Some authors did not observe 
statistically significant associations between subjective and 
objective cognitive functioning (e.g., Refs. [5, 6]). Oth-
ers showed that subjective cognitive complaints tended to 
be more frequent in patients who later developed MCI or 
dementia (33–70%), although the percentage of patients who 
complained about cognitive deficits but did not develop MCI 
or dementia was also high [7–14].
The opposite situation, i.e., a lack of subjective cognitive 
complaints in patients with objective cognitive impairments 
[4], has also been reported in PD. This ‘cognitive anosog-
nosia’ is linked to disease progression and is tightly related 
to deficits in frontal lobe and executive functioning [4, 15].
As self-awareness of cognitive performance is also asso-
ciated to motivation and emotional processing [16], the 
objective-subjective cognitive discrepancy in PD has been 
hypothesized to be moderated by psychiatric and behavioral 
symptoms [17].
To date, compelling evidence supports the idea that 
depression contributes to the objective-subjective cognitive 
discrepancy [4, 9, 12, 14, 15, 18–20]. However, no conclu-
sive evidence is available regarding the possible relation-
ship with other common behavioral symptoms in PD (e.g., 
apathy, anxiety, fatigue, sleep disorders) or demographic 
and clinical features. For example, some studies showed 
that subjective cognitive complaints were more strongly 
related to anxiety [21] or fatigue [22] than to objective cog-
nitive impairment, although other studies did not confirm 
this relationship [19]. These conflicting results may have 
stemmed from differences in the experimental designs and 
methodological approaches across studies, for instance the 
use of brief vs. more comprehensive behavioral evaluations. 
Moreover, only a few studies [14, 19] considered the poten-
tial impact of sleep disorders on the objective-subjective 
cognitive discrepancy. Yet evidence in healthy elderly [23] 
suggested that subjective cognitive measures were unlikely 
to provide accurate estimates of objective cognitive func-
tioning in presence of sleep disturbances.
Therefore, a comprehensive evaluation of behavioral 
symptoms as well as of demographic and clinical features is 
necessary to identify the factors correlated with objective-
subjective cognitive discrepancy. Thus far, only two studies 
have used this approach and both reported a close relation-
ship between depression and objective-subjective cognitive 
discrepancy. However, one study used a small sample size 
(n = 70; [19]), while the other employed an informant-based 
behavioral scale [4, 24], that is known to potentially under-
estimate symptom severity [25].
To clarify the factors related to the objective-subjective 
cognitive discrepancy has implications for clinical prac-
tice and planning therapeutic strategies in PD. In clini-
cal settings, where time resources are typically restricted, 
it is crucial to decide which depth of neuropsychological 
assessment is needed (i.e., level I screening vs. level II com-
prehensive evaluation; [1]). This clinical decision-making 
can be guided by the knowledge about the most important 
factors in determining cognitive deficits in PD, including 
the potential discrepancy between objective vs. subjective 
cognitive functioning.
In this study, we explored the main demographic, clinical, 
and patient-reported behavioral factors that were possibly 
associated to the objective-subjective cognitive discrepancy 
in a cohort of consecutive non-demented patients with PD.
Based on previous studies [9, 18, 26], we expected that 
mood disturbances severity could increase the discrepancy 
between objective and subjective cognitive functioning.
Methods
Patients and procedures
One hundred eligible patients with a clinical diagnosis of 
idiopathic PD were consecutively screened at the Movement 
Disorders outpatient clinic of the First Division of Neurol-
ogy, University of Campania “Luigi Vanvitelli” (Naples, 
Italy).
Exclusion criteria were: (1) history of cerebrovascular 
disorder or major and unstable medical disease; (2) lifetime 
or current psychotic disorders including major depressive 
episode, ascertained via the Mini International Neuropsy-
chiatric Inventory [27]; (3) dementia, following the level 
I testing procedures proposed by MDS Task Force [28], in 
terms of co-occurrence of decreased global cognitive effi-
ciency (i.e., age- and education-adjusted MoCA total score 
below Italian cut-off of 15.5 points; [29]), impairment in 
more than one cognitive domain (i.e., at least two age- and 
education-adjusted MoCA cognitive domain scores below 
Italian scores; [29]), and cognitive deficiency severe enough 
to impair daily life activities (based on medical records of 
patients’ and caregivers’ reports).
The local Ethical Committee supervised and approved all 
the procedures, following the Declaration of Helsinki. All 
participants gave their written informed consent before their 
inclusion in the study.
Demographics and clinical features
In all patients, we collected the following demographic char-
acteristics: age, education, and sex. To assess the severity of 
motor symptoms, we used the motor section of the Unified 
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Parkinson’s Disease Rating Scale (UPDRS; [30]) and the 
Hoehn and Yahr staging system (HY; [31]). The patients 
were assessed in the “ON” state, and their medication 
regimen was recorded. Daily levodopa equivalent dosage 
 (LEDDL-DOPA), daily dopamine agonist equivalent dosage 
 (LEDDDA), and the total amount of dopaminergic medica-
tion (LEDD total) were computed using Tomlinson et al.’s 
algorithm [32].
Behavioral measures
To characterize the behavioral profile of patients with PD, 
we used the Fatigue Severity Scale (FSS) [33, 34], the Beck 
Depression Inventory (BDI; [35]), the self-rated version of 
Parkinson Anxiety Scale [36, 37], and the self-rated version 
of Apathy Evaluation Scale (AES; [38, 39]). In addition, 
sleep problems were assessed via the Epworth Sleepiness 
Scale (ESS [40];) and the Parkinson’s Disease Sleep Scale 
(PDSS; [41]).
Cognitive assessment
Objective cognitive functioning was assessed with the 
Montreal Cognitive Assessment (MoCA; [29, 42]), which 
provides a total score and six subscores for selected cogni-
tive domains. The total scores were converted in age- and 
education-adjusted Z scores (MoCA adjusted Z scores; [29]). 
Higher MoCA adjusted Z scores indicate better objective 
cognitive performance. The cut-off for the presence of 
objective cognitive impairment was a MoCA adjusted Z 
score ≤ − 1.5.
Subjective cognitive complaints were assessed with the 
patient form of the Parkinson’s Disease-Cognitive Func-
tional Rating Scale (PD-CFRS; [43, 44]). This is a self-
report measure of cognitive dysfunction assessing the degree 
to which cognitive symptoms interfered with instrumental 
daily activities over the past 2 weeks. The PD-CFRS raw 
scores were converted in Z scores [45], and then multiplied 
by − 1 so to obtain Z scores (PD-CFRS Z score) with higher 
values indicating better subjective cognitive functioning. 
The cut-off for the presence of clinically significant subjec-
tive cognitive complaints was a PD-CFRS Z score ≤ − 1.5.
The discrepancy between objective and subjective cogni-
tive functioning was computed as the difference between the 
MoCA adjusted Z scores and the PD-CFRS Z scores.
On the basis of MoCA and PD-CFRS Z score cut-offs, 
patients were categorized into three groups: “Underestima-
tors”, i.e., patients with subjective cognitive complaints 
but no objective cognitive impairment (i.e., PD-CFRS Z 
score ≤ − 1.5 and MoCA adjusted Z score ≥ − 1.5); “Accu-
rate estimators”, i.e., patients with neither subjective cog-
nitive complaints nor objective cognitive impairment (i.e., 
PD-CFRS Z score and MoCA adjusted Z score ≥ − 1.5) or, 
alternatively, with both subjective cognitive complaints and 
objective cognitive impairment (i.e., PD-CFRS Z score and 
MoCA adjusted Z score ≤ − 1.5); “Overestimators”, patients 
with objective cognitive impairment but no subjective cogni-
tive complaints (i.e., PD-CFRS adjusted Z score ≥ − 1.5 and 
MoCA adjusted Z score ≤ − 1.5).
Our definition of “Underestimators” is similar to the one 
of “Subjective Cognitive Complaint” [14, 19] or “Subjec-
tive Cognitive Decline” [13, 46] which is often reported in 
the PD and Alzheimer’s disease literature. However, here, 
we used the term “Underestimators” in an operative sense, 
without diagnostic implications. Likewise, our use of the 
term “Overestimators” might recall the concept of “cogni-
tive anosognosia” [4] but also in this case we used the term 
“Overestimators” in an operational acceptation.
Statistical analyses
The data were tested for normality and values between − 1 
and 1 for asymmetry and kurtosis were considered 
acceptable.
Cohen’s kappa (κ) was calculated as a measure of agree-
ment between the patients’ subjective cognitive complaints 
(presence vs. absence) and objective evidence of cog-
nitive impairment (presence vs. absence). The strength 
of agreement was interpreted as follows: κ < 0.00 poor; 
0.00 ≤ κ ≤ 0.20 slight; 0.21 ≤ κ ≤ 0.40 fair; 0.41 ≤ κ ≤ 0.60 
moderate; 0.61 ≤ κ ≤ 0.80 substantial; 0.81 ≤ κ ≤ 1.00 almost 
perfect [47].
We compared the groups of “Accurate estimators”, 
“Underestimators”, and “Overestimators” in terms of demo-
graphic, clinical, and behavioral features using Pearson’s 
chi-square tests (χ2) for categorical variables and one-way 
analyses of variance (ANOVA) for continuous variables. 
Pairwise post-hoc comparisons were used to determine 
which groups were significantly different and the direction-
ality of the effects.
To identify the demographic, clinical, and behavioural 
features of the group of “Underestimators”, we first car-
ried out simple binary logistic regression analyses, to iden-
tify which features were able to discriminate the group of 
“Underestimators” from that of the “Non-underestimators” 
(i.e., “Overestimators” and “Accurate estimators” grouped 
together as in Ref. [48]), at a bivariate level. Second, we 
entered the features that showed a significant bivariate asso-
ciation with group membership in a multiple binary logis-
tic regression analysis model (forced entry method) to test 
which ones independently contributed to explaining patient 
classification.
The associations between the demographic, clinical, and 
behavioral features and the objective-subjective cognitive 
discrepancy (difference between the MoCA Z scores and 
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PD-CFRS) was investigated using bivariate and multiple 
linear regression analyses (forced entry method).
To check the reliability of our findings, a bootstrap 
approach (1000 bootstrap) with a 95% bias corrected and 
accelerated confidence intervals [95% CI] was used. The 
bias of an estimate can be ignored if it is lower than 0.25 
times its standard error [49].
Since the subjective cognitive complaints might have dif-
ferent implications in patients with or without objective cog-
nitive impairment, we repeated all the analyses after exclud-
ing from the “Accurate estimators” group the patients with 
both subjective cognitive complaints and objective cognitive 
impairment.
All multiple comparisons were corrected for familywise 
errors by Bonferroni’s procedures; Bonferroni corrected p 
value < 0.05 were considered statistically significant.
All statistics were performed using Statistical Package for 
Social Science version 20 (SPSS, Chicago, IL), All figures 
were created by GraphPad Prism 6.0 and Matlab.
Results
Out of 100 screened patients, eight were not willing to par-
ticipate in our study, whereas two patients were excluded (of 
these one suffered from a current major depressive episode, 
and the other was diagnosed with PD-dementia).
The demographic and clinical features of included 
patients (n = 90) did not differ from those of screened 
patients who were not included (n = 10) (Supplementary 
Table 1).
The descriptive statistics of our final sample (n = 90) were 
reported in Table 1.
Asymmetry and kurtosis were acceptable for all continu-
ous variables.
There was poor agreement between the patients’ subjec-
tive cognitive complaints and objective evidence of cogni-
tive impairment (κ = − 0.23, p = 0.01).
Of the final sample, 49 patients (54.45%) were classified 
as “Accurate estimators”, 29 (32.22%) as “Underestimators”, 
and 12 (13.33%) as “Overestimators” (Fig. 1a, b).
One-way ANOVAs and χ2 test, complemented by post-
hoc analyses, did not show statistically significant differ-
ences among “Overestimators”, “Accurate estimators”, and 
“Underestimators” in terms of demographic and clinical 
features. The group of “Underestimators” scored higher on 
the FSS, BDI, and PAS relative to the group of “Overesti-
mators” and “Accurate estimators”. The latter two groups 
did not differ between each other in terms of any behavioral 
feature considered. The group of “Underestimators” scored 
lower on the PD-CFRS than the group of “Overestimators” 
and “Accurate estimators”. Relatively to the other groups, 
the group of “Overestimators” scored lower on the MoCA 
total score and the attention and working memory subscore 
of the MoCA (Table 2).
The simple binary logistic regression analyses showed 
that neither the demographic nor the clinical features could 
distinguish the group of “Underestimators” from that of the 
“Non-underestimators” (i.e., “Overestimators” or “Accurate 
estimators” grouped together as in Ref [48]). In contrast, 
the FSS, BDI, PAS, and AES were able to distinguish the 
Table 1  Overall sample descriptive statistics (n = 90)
SD standard deviation, UPDRS Unified Parkinson’s Disease Rating 
Scale, LEDD levodopa equivalent daily dose, MoCA Montreal Cogni-
tive Assessment, WM working memory, PD-CFRS Parkinson’s Dis-
ease Cognitive Functional Rating Scale
a Adjusted according to age, education, or sex
Variable Mean (SD) or count (%)
Demographics
 Age 66.74 (9.22)
 Education, years 9.66 (4.09)
 Sex, male 53 (58.90%)
Clinical features
 Age at onset 61.63 (9.72)
 Disease duration, years 5.25 (2.92)
 UPDRS-III 27.33 (9.57)
 Hoehn and Yahr stage 2.00 (0.37)
 LEDD total (mg/day) 516.82 (233.37)
  LEDDDA (mg/day) 71.23 (106.27)
  LEDDL-DOPA (mg/day) 386.16 (259.29)
Behavioural measures
 Fatigue Severity Scale 3.47 (1.88)
 Beck Depression Inventory 8.91 (7.45)
 Parkinson Anxiety Scale 11.92 (9.26)
 Apathy Evaluation Scale 31.74 (7.55)
 Parkinson’s disease sleep scale 114.95 (22.23)
 Epworth Sleepiness Scale 5.77 (4.19)
Cognitive assessment
 MoCA total
  Raw score 20.02 (4.87)
  Adjusted  scorea 22.46 (4.31)
  Adjusted Z  scorea 0.18 (1.42)
 MoCA adjusted  subscoresa
  Memory 1.29 (1.47)
  Visuospatial abilities 0.68 (1.40)
  Executive functions 0.78 (1.77)





  Z score − 0.68 (2.32)
  MoCA (Z score) minus PD-CFRS (Z 
score)
− 0.64 (2.30)
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“Underestimators” from “Non-underestimators”. However, 
the multiple binary logistic regression analysis revealed that 
only the BDI and FSS were independently able to classify 
the “Underestimators” vs. “Non-underestimators” with an 
overall accuracy of 76% (Table 3).
The bivariate linear regression analyses showed that 
higher scores on FSS, BDI, PAS, AES, and ESS were associ-
ated with a greater discrepancy between PD-CFRS Z scores 
and the MoCA adjusted Z scores. The multiple linear regres-
sion analysis indicated that only the FSS and BDI were sig-
nificantly associated with a discrepancy between the MoCA 
Z scores and the PD-CFRS Z scores and with an overall 
model accuracy of 42% (Table 4; Fig. 2).
The results were confirmed after the exclusion of patients 
who showed a congruency between subjective cognitive 
complaints and objective cognitive impairment (n = 5) from 
the “Accurate estimators” group (Supplementary Tables 2, 
3, 4, 5).
The bootstrapping procedure did not reveal substantial 
biases, and confirmed that our sample size was adequate to 
detect statistically meaningful effects [49].
Discussion
We studied the extent to which the objective-subjective cog-
nitive discrepancy in PD was associated with demographic, 
clinical, and patient-reported behavioral features.
Three main results emerged. First, there was poor agree-
ment between patient subjective reports and patient objec-
tive deficits, as > 45% of patients showed objective-subjec-
tive cognitive discrepancy. Second, the underestimation 
of cognitive performance in PD was associated with the 
severity of fatigue and depressive symptoms but not with 
the demographics or clinical features. This supports the idea 
that specific behavioral symptoms are the main correlates 
of objective-subjective cognitive discrepancy in PD [4, 14, 
19, 21]. Third, the overestimation of cognitive performance 
was tightly associated with frontal executive impairments.
Our first main finding demonstrated that the objective-
subjective cognitive discrepancy is a remarkable clinical 
phenomenon in PD. Indeed, 32% of patients had subjective 
cognitive complaints but no objective cognitive impairment 
(“Underestimators”), while a 13% showed an inverse pattern 
(i.e., objective cognitive impairment but no subjective cogni-
tive complaint, “Overestimators”). These findings highlight 
that underestimation of one’s own cognitive abilities is com-
mon and clinically relevant in PD [13, 14], consistent with 
a recent study, in which the objective-subjective cognitive 
discrepancy occurred in 45% of patients with PD, with a 
higher percentage (24%) of patients underestimating their 
objective cognitive abilities and a lower percentage (21%) 
overestimating it [4].
These results showed that not all PD patients with objec-
tive cognitive impairments are able to report their real cog-
nitive performance, whereas not all PD patients reporting 
cognitive problems display ‘objective’ deficits [5]. As the 
clinical diagnosis of MCI in PD sometimes relies on cogni-
tive impairments typically reported by the patient or inform-
ant [1], our findings suggest caution in relying on patients’ 
subjective reports, especially in the absence of objective 
testing [6].
Our second main finding showed that severity of fatigue, 
depressive, and anxious symptoms distinguished “Under-
estimators” from “Overestimators” and “Accurate estima-
tors”. The link between cognitive underestimation and 
fatigue has been consistently demonstrated in patients 
with multiple sclerosis (e.g., Refs. [48, 50]). However, this 
association has been scarcely investigated in PD, and con-
flicting results have been reported [19, 22]. In PD, Kluger 
et al. [51] proposed that fatigue, defined as a significantly 
diminished level of energy or increased perception of effort 
Fig. 1  a Patients grouped 
according to the presence of 
objective cognitive impair-
ment and subjective cognitive 
complaint. b Percentage of 
overestimators, accurate estima-
tors, and underestimators
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that is disproportionate to attempted activities [52], may be 
linked more to altered subjective awareness than to actual 
performance limitations. Indeed, fatigued patients often 
report subjective complaints of increased sense of effort or 
decreased stamina that are not related to objective decrement 
in performance [51]. In keeping with these findings, our 
group of “Underestimators” reported subjective complaints 
of cognitive deficits which were not supported by objective 
evidence of cognitive impairment.
Such link between fatigue and cognitive underestima-
tion may stem, at least in part, from altered self-awareness 
(e.g., exaggeration of deficits or hyperawareness). According 
to Rosen’s model [16], accurate self-awareness of perfor-
mance depends on active monitoring of task performance, 
which results from comparing current performance with task 
demands and with the level of performance that is consid-
ered acceptable (e.g., a certain number of errors could be 
considered acceptable on a given task). Therefore, fatigue 
symptoms in “Underestimators” might be ascribed to altera-
tions in self-awareness caused by inefficient monitoring of 
sensorimotor and cognitive processes. Recent evidence 
seems to support this speculation [53], but future studies 
are required.
“Underestimators” also showed more depressive and anx-
ious symptoms than the two other groups, which is consist-
ent with previous studies in PD [9, 12, 14, 18–20]. Together, 
these findings demonstrate a tight association between self-
awareness of cognitive performance and emotional process-
ing [16]. Nevertheless, it remains unclear if mood symp-
toms alter self-awareness or whether a pre-existing deficit 
in self-awareness is antecedent to the development of mood 
symptoms [15]. It is also possible that more severe mood 
symptoms reported by the “Understimators” foster a nega-
tive bias in reporting problems or contribute to exaggerating 
the cognitive deficits (hyperawareness). This is because a 
negative and pessimistic vision of oneself, the environment, 
and the future is at the core of several mood disturbances 
[54].
Our third main finding revealed that, compared to the 
other groups, the “Overestimators” scored lower on the 
attention and working memory subscore of the MoCA 
(deriving from cognitive subtests such as Digit Span Back-
ward [55], Serial 7 subtractions [56]). These results reinforce 
the evidence of an association between frontal executive 
impairments and poor self-awareness of cognitive deficits 
in PD [4, 15, 57], which is also in line with models of ano-
sognosia in Alzheimer’s disease [58].
Additional analyses corroborated our findings and con-
firmed their statistical robustness. First, we found that our 
main findings held when the “Overestimators” and “Accu-
rate estimators” were merged in the same group (“Non-
underestimators”) and compared to the group of “Underesti-
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similar results when we explored the factors associated with 
objective-subjective cognitive discrepancy (i.e., the differ-
ence between the MoCA Z scores and PD-CFRS) via the 
linear regression analyses in the whole patient sample.
When all the behavioural symptoms were evaluated 
simultaneously (by logistic or linear multiple regression 
analyses), depressive but not anxious symptoms were asso-
ciated with the objective-subjective cognitive discrepancy. 
These results suggested that specific facets of depression, 
rather than those shared with anxiety (e.g., loss of energy) 
[59], may play a pivotal role in objective-subjective cogni-
tive discrepancy. Interestingly, patients who are depressed, 
but not necessarily anxious, typically express negative 
beliefs about themselves (e.g., cognitive underestimation), 
the world, and the future [60].
All these findings highlight the importance of assess-
ing and monitoring fatigue and depressive symptoms in 
PD, especially when patients’ complaints of cognitive 
impairment are used as prognostic indicators of future objec-
tive cognitive deterioration (e.g., Refs. [10, 13, 14]).
We are aware that one limitation of the present study 
relates to the tools used to assess subjective cognitive com-
plaints and objective cognitive impairment. As Jessen et al. 
[46] highlighted, a neuropsychological battery covering all 
domains is necessary for accurately evaluating the ‘mis-
match’ between subjective and objective cognitive perfor-
mance. The PD-CFRS has been validated as a measure of 
self-perceived impact of cognitive changes on daily func-
tioning [43, 45], and provides only an indirect measure of 
subjective complaints of cognitive impairment. PD-CFRS 
is available in Italian and has been used in similar stud-
ies in PD [26], although it may be less specific than other 
scales (for a review, see Ref. [17]). The MoCA is a cognitive 
screening tool but is less sensitive to domain-specific dys-
functions than comprehensive neuropsychological batteries 
[1]. The use of MoCA and PD-CFRS may have partially 
Table 3  Simple and multiple 
binary logistic regression 
analyses assessing which 
demographics, clinical, 
and behavioural features 
distinguished underestimators 
from non-underestimators; 95% 
bias corrected and accelerated 
confidence intervals [95% CI] 
(1000 bootstrap samples) for the 
logistic regression coefficients 
were reported in parentheses
Statistically significant variables are shown in bold
SE standard error, OR odds ratio, CI confidence interval,  UPDRS Unified Parkinson’s Disease Rating 
Scale, LEDD levodopa equivalent daily dose
a Coded as: 0 = male, 1 = female
b p value related to unstandardized beta coefficient using the Wald statistic
c Model χ2 (4) = 33.01, p value < 0.01, R2 = 0.44 (Nagelkerke)
Variable Estimate [CI 95%] Bias SE p  valueb OR [CI 95%]
Simple regression
 Demographics
  Age 0.02 [− 0.03, 0.07] 0.00 0.02 0.399 1.02 [0.97, 1.07]
  Education, years − 0.09 [− 0.22, 0.01] − 0.00 0.06 0.101 0.90 [0.80, 1.01]
   Sexa − 0.43 [− 1.29, 0.50] 0.04 0.45 0.342 0.64 [0.26, 1.58]
 Clinical features
  Age at onset 0.02 [− 0.02, 0.07] − 0.00 0.02 0.379 1.02 [0.97, 1.07]
  Disease duration, years 0.03 [− 0.13, 0.20] − 0.00 0.08 0.691 1.03 [0.88, 1.19]
  UPDRS-III 0.01 [− 0.02, 0.06] 0.00 0.02 0.520 1.01 [0.96, 1.06]
  Hoehn and Yahr stage 0.80 [− 0.27, 2.49] 0.40 2.74 0.222 2.22 [0.61, 8.07]
  LEDD total (mg/day) 0.00 [− 0.00, 0.00] 0.00 0.00 0.496 1.00 [0.99, 1.00]
   LEDDDA (mg/day) − 0.00 [− 0.00, 0.00] 0.00 0.00 0.212 0.99 [0.99, 1.00]
   LEDDL-DOPA (mg/day) 0.00 [− 0.00, 0.00] 0.00 0.00 0.471 1.00 [0.99, 1.00]
 Behavioural measures
  Fatigue Severity Scale 0.57 [0.30, 0.93] 0.02 0.15 < 0.001 1.77 [1.32, 2.38]
  Beck Depression Inventory 0.15 [0.08, 0.26] 0.01 0.05 < 0.001 1.15 [1.07, 1.24]
  Parkinson Anxiety Scale 0.10 [0.05, 0.16] 0.00 0.02 < 0.001 1.10 [1.04, 1.16]
  Apathy Evaluation Scale 0.10 [0.03, 0.19] 0.00 0.04 0.024 1.10 [1.01, 1.20]
  Parkinson’s disease sleep scale − 0.01 [− 0.04, 0.00] − 0.00 0.01 0.228 0.98 [0.96, 1.00]
  Epworth Sleepiness Scale 0.05 [− 0.05, 0.18] 0.00 0.06 0.327 1.05 [0.94, 1.16]
Multiple  regressionc
 Fatigue Severity Scale 0.57 [0.09, 1.44] 0.05 0.35 0.008 1.77 [1.16, 2.71]
 Beck Depression Inventory 0.11 [0.01, 0.32] 0.01 0.07 0.035 1.12 [1.00, 1.25]
 Parkinson Anxiety Scale 0.01 [− 0.08, 0.10] 0.00 0.05 0.702 1.01 [0.93, 1.09]
 Apathy Evaluation Scale − 0.06 [− 0.20, 0.04] − 0.01 0.06 0.938 0.95 [0.85, 1.02]
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inflated the objective-subjective cognitive discrepancy. 
Indeed, the cognitive functions implied in daily activities, 
as explored by PD-CFRS, may not necessarily parallel those 
needed to perform a cognitive screening test. Consequently, 
patients classified as “Understimators” may be affected by 
an objective cognitive impairment undetected by MoCA. 
On the other hand, as MoCA is a cognitive screening test 
recommended by the MDS, widely used in clinical practice 
and research, this could help ensuring a reasonable gener-
alization of our results [11, 20]. Moreover, we considered 
MoCA subscores to increase the explanatory power of our 
results and to provide a more nuanced assessment of objec-
tive cognitive functioning [61].
An additional limitation of this study is its cross-sectional 
nature which calls for replication by longitudinal study 
designs, by which it is possible to explore the predictive 
relationship between the self-experienced worsening of cog-
nitive capacities and the objective cognitive deterioration 
[46]. Furthermore, to screen the presence of PD dementia, 
we used the level I testing procedures which, compared to 
level II ones, do not allow to specify the pattern and sever-
ity of the cognitive impairment and may lead to suboptimal 
recruitment decisions [28]. Finally, the low percentage of 
“Overestimators” did not enable us to use more powerful 
statistical methods, such as multinomial logistic regression 
analyses, to characterize the profile of this group.
Despite these shortcomings, our findings provide further 
insights on the main factors correlated with the discrepancy 
between objective and subjective cognitive functioning in 
PD. Accurate detection of cognitive impairment is crucial 
for guiding treatments and neuropsychological assessment in 
a patient-centered manner. This calls for a need of increased 
awareness of ‘core’ behavioral symptoms such as fatigue and 
depression, which are likely antecedents of the discrepancy 
between objective cognitive impairments and subjective 
cognitive complaints in PD.
Table 4  Simple and multiple 
linear regression analyses 
assessing which demographics, 
clinical, and behavioural 
features were associated with 
the discrepancy between 
objective and subjective 
cognitive functioning (MoCA 
Z scores minus PD-CFRS Z 
scores) in overall sample; 95% 
bias corrected and accelerated 
confidence intervals [95% CI] 
(1000 bootstrap samples) for 
the linear regression coefficients 
were reported in parentheses
Statistically significant variables are shown in bold
a Coded as: 0 = male, 1 = female
b Model (F test) = 10.89, p value < 0.001, R2 = 0.42
SE standard error, CI confidence interval, UPDRS Unified Parkinson’s Disease Rating Scale, LEDD levo-
dopa equivalent daily dose
Variable Estimate [CI 95%] SE Bias β p value
Simple regression
 Demographics
  Age 0.02 [− 0.03, 0.07] 0.02 0.00 0.07 0.468
  Education, years − 0.09 [− 0.18, 0.04] 0.05 0.00 − 0.14 0.186
   Sexa − 0.23 [− 1.26, 0.74] 0.52 − 0.00 − 0.04 0.674
 Clinical features
  Age at onset 0.03 [− 0.02, 0.09] 0.02 0.00 0.12 0.236
  Disease duration, years − 0.15 [− 0.32, 0.08] 0.10 0.01 − 0.17 0.096
  UPDRS-III 0.00 [− 0.04, 0.04] 0.02 0.00 − 0.02 0.799
  Hoehn and Yahr stage 0.26 [− 0.80, 1.33] 0.53 − 0.02 0.03 0.721
  LEDD total (mg/day) − 0.00 [− 0.00, 0.00] 0.00 0.00 − 0.07 0.505
   LEDDDA (mg/day) − 0.00 [− 0.00, 0.00] 0.00 0.00 − 0.08 0.422
   LEDDL-DOPA (mg/day) 0.00 [− 0.00, 0.00] 0.00 0.00 − 0.04 0.714
 Behavioural measures
  Fatigue Severity Scale 0.69 [0.39, 0.99] 0.15 − 0.00 0.51 < 0.001
  Beck Depression Inventory 0.18 [0.10, 0.25] 0.03 0.00 0.53 < 0.001
  Parkinson Anxiety Scale 0.11 [0.05, 0.16] 0.02 0.00 0.40 < 0.001
  Apathy Evaluation Scale 0.09 [0.03, 0.16] 0.03 0.00 0.27 0.010
  Parkinson’s disease sleep scale − 0.01 [− 0.04, 0.00] 0.01 0.00 − 0.15 0.171
  Epworth Sleepiness Scale 0.15 [0.01, 0.34] 0.08 0.00 0.25 0.015
Multiple  regressionb
 Fatigue Severity Scale 0.42 [0.09, 0.82] 0.17 0.00 0.31 0.007
 Beck Depression Inventory 0.13 [0.03, 0.23] 0.05 0.00 0.39 0.004
 Parkinson Anxiety Scale 0.00 [− 0.05, 0.06] 0.02 − 0.00 0.02 0.823
 Apathy Evaluation Scale − 0.01 [− 0.07, 0.04] 0.03 0.00 − 0.05 0.575
 Epworth Sleepiness Scale 0.00 [− 0.10, 0.11] 0.07 0.00 0.00 0.929
3453Journal of Neurology (2021) 268:3444–3455 
1 3
The further implications of our study are threefold. First, 
caution should be exercised when making a clinical diag-
nosis of MCI, especially when MCI is diagnosed only in 
terms of subjectively-reported cognitive complaints [1, 6]. 
Second, clinicians should include an assessment of fatigue 
and depression in their routine cognitive examination to 
determine to extent to which these behavioral factors influ-
ence cognitive complains. Third, our data might suggest that 
behavioral and/or pharmacological interventions for fatigue 
and depression could reduce subjective cognitive complaints 
[62].
Enhancing patients’ abilities to correctly perceive their 
individual level of cognitive functioning has great potential 
to improve their own and their caregivers’ quality of life.
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